ReviewPharmaceutical research2026
The Role of Cyclodextrins in Modulating Stimuli-Responsiveness for Anticancer Drug Delivery.
Review in Pharmaceutical research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
backgroundThe precision delivery of active pharmaceutical ingredients remains a major challenge in modern pharmacology, where conventional therapies often lack selectivity and cause severe side effects. Stimuli-responsive drug delivery systems (SRDDS) represent a promising strategy to achieve controlled release in response to pathological microenvironments or external triggers. While various organic and inorganic carriers have been investigated, cyclodextrins (CDs) occupy a unique position due to their biocompatibility, safety record, and distinctive molecular architecture. Beyond their established role as solubilizing excipients, CDs can act as a fundamental component capable of driving responsiveness within drug delivery systems.
objectiveThis review highlights cyclodextrin-based stimuli-responsive systems (SRCDS) in which CDs themselves mediate responsiveness, rather than serving as simple structural elements. SCOPE AND FOCUS: A comparative discussion of different responsive mechanisms is provided, offering insights into the design principles that may accelerate the clinical translation of CD-based SRDDS. A particular focus will be provided to chemical structure components exerting stimuli responsiveness. In addition, recent publications on SRCDS with pharmacological or biological experimental investigations and relevance are reviewed, with particular attention to applications in cancer therapy.
Indexed as
Identifiers
41986603What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.